In the A20 mRNA-LNP treatment group, lung fibrosis was effectively inhibited by modulating the DREAM–SMAD2 pathway in the bleomycin-induced SSc model (Figure 5). The gene discussed is TNFAIP3; the disease is pulmonary fibrosis.